mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)

Kinase Inhibitor ◽

Mtor Inhibitors ◽

Cancer Resistance ◽

P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor

Drug Metabolism Letters ◽

10.2174/187231210792928279 ◽

2010 ◽

Vol 4 (4) ◽

pp. 202-212 ◽

Cited By ~ 31

Author(s):

Johnny J. Yang ◽

Mark N. Milton ◽

Shaoxia Yu ◽

Mingxiang Liao ◽

Ning Liu ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Breast Cancer Resistance Protein ◽

Kinase Inhibitor ◽

Cancer Resistance ◽

P Glycoprotein ◽

Resistance Protein

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

10.1158/0008-5472.sabcs-09-5060 ◽

2009 ◽

Cited By ~ 18

Author(s):

T. Hickish ◽

D. Wheatley ◽

N. Lin ◽

L. Carey ◽

S. Houston ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Her2 Positive ◽

Bibw 2992 ◽

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Cancer Management and Research ◽

10.2147/cmar.s321428 ◽

2021 ◽

Vol Volume 13 ◽

pp. 7165-7174

Author(s):

Ying Sun ◽

Beibei Chen ◽

Jisheng Li ◽

Ling Peng ◽

Shuguang Li ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Real World ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1065 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1065-1065 ◽

Cited By ~ 6

Author(s):

M. H. Schuler ◽

M. M. Uttenreuther-Fischer ◽

M. J. Piccart-Gebhart ◽

N. Harbeck ◽

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Bibw 2992 ◽

BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies.

10.1158/0008-5472.sabcs-09-5062 ◽

2009 ◽

Cited By ~ 2

Author(s):

N. Harbeck ◽

M. Schmidt ◽

P. Harter ◽

K. Possinger ◽

W. Jonat ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Bibw 2992 ◽

194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer

Molecular Therapy ◽

10.1016/s1525-0016(16)35998-6 ◽

2012 ◽

Vol 20 ◽

pp. S77

Keyword(s):

Breast Cancer ◽

T Lymphocytes ◽

Tyrosine Kinase ◽

Cytotoxic T Lymphocytes ◽

Kinase Inhibitor

PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.034 ◽

2006 ◽

Vol 79 (2) ◽

pp. P10-P10 ◽

Cited By ~ 2

Author(s):

F GUO ◽

S LETRENT ◽

D NOE ◽

A QIN ◽

K ROHRBACHER ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Her2 Positive ◽

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/s0360-3016(00)01358-4 ◽

2000 ◽

Vol 48 (5) ◽

pp. 1519-1528 ◽

Cited By ~ 78

Author(s):

Geetha S Rao ◽

Susan Murray ◽

Stephen P Ethier

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Cancer Cells ◽

Receptor Tyrosine Kinase ◽

Human Breast Cancer ◽

Breast Cancer Cells ◽

Kinase Inhibitor ◽

Human Breast Cancer Cells ◽

Human Breast

Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET

International Journal of Cancer ◽

10.1002/ijc.31915 ◽

2018 ◽

Vol 144 (3) ◽

pp. 651-664 ◽

Cited By ~ 6

Author(s):

Yingying Shen ◽

Wei Zhang ◽

Jianghua Liu ◽

Jun He ◽

Renxian Cao ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patient ◽

Tyrosine Kinase ◽

Breast Cancer Patient ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Therapeutic Activity

Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation

Journal of Experimental & Clinical Cancer Research ◽

10.1186/s13046-019-1164-5 ◽

2019 ◽

Vol 38 (1) ◽

Cited By ~ 11

Author(s):

Luigi Mele ◽

Marcella la Noce ◽

Francesca Paino ◽

Tarik Regad ◽

Sarah Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Kinase Inhibitor ◽

Glucose 6 Phosphate Dehydrogenase